Computational analysis maps how phytocannabinoids may treat neurodegenerative diseases

Network pharmacology of 8 phytocannabinoids revealed interaction with 10 of 60 neurodegenerative disease targets, with enrichment of ErbB and PI3K-Akt signaling pathways. CBD modifies DNA and mitochondrial DNA in the hippocampus, potentially protecting against epilepsy, depression, and Parkinson's. Effects vary across sex, disease state, and age.

Extensive literature review combined with bioinformatics, network pharmacology, and enrichment analysis to map phytocannabinoid interactions with neuromodulatory pathways across metabolomics, transcriptomic, and epigenetic studies.

Understanding the specific molecular pathways through which cannabinoids affect neurodegenerative diseases could guide development of targeted therapies and identify which patients are most likely to benefit.

The finding that cannabinoid effects vary by sex, disease state, and age echoes a broader theme in cannabis research: one-size-fits-all approaches are inadequate. Computational approaches like network pharmacology can help predict which patients might respond to specific cannabinoid combinations.

Computational and bioinformatics analysis needs experimental validation. Network pharmacology identifies potential interactions, not proven mechanisms. Many findings derived from cell line and animal model data with limited human validation.